Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology
Abstract
:1. Introduction
2. Results
2.1. Modelling Analysis
2.1.1. GNAQ p.Gly48Leu
2.1.2. FGFR4 p.Cys172Gly
2.2. Case Description
3. Discussion
4. Materials and Methods
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
Abbreviations
AJCC | American Joint Committee on Cancer |
BAM | Binary alignment map |
FFPE | Formalin-fixed paraffin-embedded |
FGF | Fibroblast growth factors |
FGFR | Fibroblast growth factor receptor |
Gαi | Guanine nucleotide-binding protein G(i) subunit alpha-1 |
Gαq | Guanine nucleotide-binding protein G(q) subunit alpha chimeric protein |
GPCR | G protein-coupled receptor family |
GDP | Guanosine 5′-diphosphate |
GTP | Guanosine 5′-triphosphate |
MRI | Magnetic resonance imaging |
MTB | Molecular tumor board |
NEMO | NRAS-mutant melanoma |
NGS | Next generation sequencing |
PET-CT | Positron emission tomography-computed tomography |
PDB | Protein Data Bank |
SRS | Stereotactic radiosurgery |
SUV | Standardized uptake value |
SW | Switch region |
TMB | Tumor mutation burden |
TPS | Tumor Proportion Score |
References
- Lundstrom, K. An overview on GPCRs and Drug Discovery: Structure-based Drug Design and Structural Biology on GPCRs. In G Protein-Coupled Receptors in Drug Discovery; Leifert, W., Ed.; Humana Press: Totowa, NJ, USA, 2009; pp. 51–66. [Google Scholar] [CrossRef]
- Syrovatkina, V.; Alegre, K.O.; Dey, R.; Huang, X.Y. Regulation, Signaling, and Physiological Functions of G-Proteins. J. Mol. Biol. 2016, 428, 3850–3868. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Neves, S.R.; Ram, P.T.; Iyengar, R. G protein pathways. Science 2002, 296, 1636–1639. [Google Scholar] [CrossRef] [PubMed]
- Shoushtari, A.N.; Carvajal, R.D. GNAQ and GNA11 mutations in uveal melanoma. Melanoma Res. 2014, 24, 525–534. [Google Scholar] [CrossRef] [PubMed]
- Decatur, C.L.; Ong, E.; Garg, N.; Anbunathan, H.; Bowcock, A.M.; Field, M.G.; Harbour, J.W. Driver mutations in uveal melanoma associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016, 134, 728–733. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2, 401–404. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Waldo, G.L.; Ricks, T.K.; Hicks, S.N.; Cheever, M.L.; Kawano, T.; Tsuboi, K.; Wang, X.; Montell, C.; Kozasa, T.; Sondek, J.; et al. Kinetic scaffolding mediated by a phospholipase C-β and Gq signaling complex. Science 2010, 330, 974–980. [Google Scholar] [CrossRef] [Green Version]
- Nishimura, A.; Kitano, K.; Takasaki, J.; Taniguchi, M.; Mizuno, N.; Tago, K.; Hakoshima, T.; Itoh, H. Structural basis for the specific inhibition of heterotrimeric G q protein by a small molecule. Proc. Natl. Acad. Sci. USA 2010, 107, 13666–13671. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Farrell, B.; Breeze, A.L. Structure, activation and dysregulation of fibroblast growth factor receptor kinases: Perspectives for clinical targeting. Biochem. Soc. Trans. 2018, 46, 1753–1770. [Google Scholar] [CrossRef]
- Chen, X.; Wu, Q.; Tan, L.; Porter, D.; Jager, M.J.; Emery, C.; Bastian, B.C. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene 2014, 33, 4724–4734. [Google Scholar] [CrossRef] [Green Version]
- Cheng, Y.; Tian, H. Current development status of MEK inhibitors. Molecules 2017, 22, 1551. [Google Scholar] [CrossRef] [Green Version]
- Johansson, P.; Aoude, L.G.; Wadt, K.; Glasson, W.J.; Warrier, S.K.; Hewitt, A.W.; Kiilgaard, J.F.; Heegaard, S.; Isaacs, T.; Franchina, M.; et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 2016, 7, 4624–4631. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Simanshu, D.K.; Nissley, D.V.; McCormick, F. RAS Proteins and Their Regulators in Human Disease. Cell 2017, 170, 17–33. [Google Scholar] [CrossRef] [Green Version]
- Chang, M.T.; Asthana, S.; Gao, S.P.; Lee, B.H.; Chapman, J.S.; Kandoth, C.; Gao, J.J.; Socci, N.D.; Solit, D.B.; Olshen, A.B.; et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 2016, 34, 155–163. [Google Scholar] [CrossRef]
- Chang, M.T.; Bhattarai, T.S.; Schram, A.M.; Bielski, C.M.; Donoghue, M.T.A.; Jonsson, P.; Chakravarty, D.; Phillips, S.; Kandoth, C.; Penson, A.; et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov. 2018, 8, 174–183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bakhoum, M.F.; Esmaeli, B. Molecular characteristics of uveal melanoma: Insights from the cancer genome atlas (TCGA) project. Cancers 2019, 11, 1061. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liau, J.-Y.; Lee, J.-C.; Tsai, J.-H.; Chen, C.-C.; Chung, Y.-C.; Wang, Y.-H. High frequency of GNA14, GNAQ, and GNA11 mutations in cherry hemangioma: A histopathological and molecular study of 85 cases indicating GNA14 as the most commonly mutated gene in vascular neoplasms. Mod. Pathol. 2019. [Google Scholar] [CrossRef] [PubMed]
- Joseph, N.M.; Brunt, E.M.; Marginean, C.; Nalbantoglu, I.L.K.; Snover, D.C.; Thung, S.N.; Yeh, M.M.; Umetsu, S.E.; Ferrell, L.D.; Gill, R.M. Frequent GNAQ and GNA14 mutations in hepatic small vessel neoplasm. Am. J. Surg. Pathol. 2018, 42, 1201–1207. [Google Scholar] [CrossRef]
- Schymkowitz, J.; Borg, J.; Stricher, F.; Nys, R.; Rousseau, F.; Serrano, L. The FoldX web server: An online force field. Nucleic Acids Res. 2005, 33, 382–388. [Google Scholar] [CrossRef] [Green Version]
- Potapov, V.; Cohen, M.; Schreiber, G. Assessing computational methods for predicting protein stability upon mutation: Good on average but not in the details. Protein Eng. Des. Sel. 2009, 22, 553–560. [Google Scholar] [CrossRef] [Green Version]
- Huhtala, M.T.; Pentikainen, O.T.; Johnson, M.S. A dimeric ternary complex of FGFR1, heparin and FGF-1 leads to an “electrostatic sandwich” model for heparin binding. Structure 1999, 7, 699–709. [Google Scholar] [CrossRef] [Green Version]
- Sarabipour, S.; Hristova, K. Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure. J. Mol. Biol. 2016, 428, 3903–3910. [Google Scholar] [CrossRef] [Green Version]
- Cleary, J.M.; Raghavan, S.; Li, Y.Y.; Spurr, L.; Wu, Q.; Shi, L.; Brais, L.K.; Odhiambo, Z.; Goyal, L.; Patel, A.K.; et al. Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma. J. Clin. Oncol. 2020, 38, 567. [Google Scholar] [CrossRef]
- Fancello, L.; Gandini, S.; Pelicci, P.G.; Mazzarella, L. Tumor mutational burden quantification from targeted gene panels: Major advancements and challenges. J. Immunother. Cancer 2019, 7, 183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goodman, A.M.; Kato, S.; Bazhenova, L.; Patel, S.P.; Frampton, G.M.; Miller, V.; Stephens, P.J.; Daniels, G.A.; Kurzrock, R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 2017, 16, 2598–2608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carvajal, R.D.; Piperno-Neumann, S.; Kapiteijn, E.; Chapman, P.B.; Frank, S.; Joshua, A.M.; Piulats, J.M.; Wolter, P.; Cocquyt, V.; Chmielowski, B.; et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). J. Clin. Oncol. 2018, 36, 1232–1239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carvajal, R.D.; Schwartz, G.K.; Mann, H.; Smith, I.; Nathan, P.D. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). BMC Cancer 2015, 15, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Shoushtari, A.N.; Kudchadkar, R.R.; Panageas, K.; Murthy, R.K.; Jung, M.; Shah, R.; O’Donnell, B.; Khawaja, T.T.; Shames, Y.; Prempeh-Keteku, N.A.; et al. A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma. J. Clin. Oncol. 2016, 34, 9511. [Google Scholar] [CrossRef]
- Dummer, R.; Schadendorf, D.; Ascierto, P.A.; Arance, A.; Dutriaux, C.; Giacomo, A.M.D.; Rutkowski, P.; Vecchio, M.D.; Gutzmer, R.; Mandala, M.; et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017, 18, 435–445. [Google Scholar] [CrossRef]
- Kuske, M.; Westphal, D.; Wehner, R.; Schmitz, M.; Beissert, S.; Praetorius, C.; Meier, F. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy. Pharmacol. Res. 2018, 136, 151–159. [Google Scholar] [CrossRef]
- Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.C. UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612. [Google Scholar] [CrossRef] [Green Version]
- Bateman, A.; Martin, M.J.; O’Donovan, C.; Magrane, M.; Apweiler, R.; Alpi, E.; Antunes, A.; Arganiska, J.; Bely, B.; Bingley, M.; et al. UniProt: A hub for protein information. Nucleic Acids Res. 2015, 43, 204–212. [Google Scholar] [CrossRef]
- The UniProt Consortium. UniProt: The universal protein knowledgebase. Nucleic Acids Res. 2017, 45, 158–169. [Google Scholar] [CrossRef] [PubMed]
- Edgar, R.C. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004, 32, 1792–1797. [Google Scholar] [CrossRef] [Green Version]
- Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235–242. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tesmer, V.M.; Kawano, T.; Shankaranarayanan, A.; Kozasa, T.; Tesmer, J.J.G. Snapshot of Activated G Proteins at the Membrane: The Gαq-GRK2-Gßγ Complex. Science 2005, 310, 1686–1690. [Google Scholar] [CrossRef]
- Lyon, A.M.; Dutta, S.; Boguth, C.A.; Skiniotis, G.; Tesmer, J.J.G. Full-length Gαq-phospholipase C-β3 structure reveals interfaces of the C-terminal coiled-coil domain. Nat. Struct. Mol. Biol. 2013, 20, 355–362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lyon, A.M.; Tesmer, J.J.G. Structural insights into phospholipase C-β function. Mol. Pharmacol. 2013, 84, 488–500. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taylor, V.G.; Bommarito, P.A.; Tesmer, J.J.G. Structure of the Regulator of G Protein Signaling 8 (RGS8)-Gα q Complex. J. Biol. Chem. 2016, 291, 5138–5145. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Krebs, F.S.; Gérard, C.; Wicky, A.; Aedo-Lopez, V.; Missiaglia, E.; Bisig, B.; Trimech, M.; Michielin, O.; Homicsko, K.; Zoete, V. Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology. Int. J. Mol. Sci. 2020, 21, 8021. https://doi.org/10.3390/ijms21218021
Krebs FS, Gérard C, Wicky A, Aedo-Lopez V, Missiaglia E, Bisig B, Trimech M, Michielin O, Homicsko K, Zoete V. Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology. International Journal of Molecular Sciences. 2020; 21(21):8021. https://doi.org/10.3390/ijms21218021
Chicago/Turabian StyleKrebs, Fanny S., Camille Gérard, Alexandre Wicky, Veronica Aedo-Lopez, Edoardo Missiaglia, Bettina Bisig, Mounir Trimech, Olivier Michielin, Krisztian Homicsko, and Vincent Zoete. 2020. "Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology" International Journal of Molecular Sciences 21, no. 21: 8021. https://doi.org/10.3390/ijms21218021